Cytokinetics (NASDAQ:CYTK) reported quarterly losses of $(1.50) per share which missed the analyst consensus estimate of $(1.45) by 3.45 percent. This is a 19.05 percent decrease over losses of $(1.26) per share from the same period last year. The company reported quarterly sales of $17.755 million which beat the analyst consensus estimate of $6.911 million by 156.90 percent. This is a 4.89 percent increase over sales of $16.927 million the same period last year.